Records containing: Melanoma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-01-30Launching the Era of Melanoma Survivorship: Defining Benchmarks in Quality of Life Inclusive of Mental Health (QOL-MH)
-
CLINICAL_TRIALS study record update · 2026-01-29A Phase 1 Study of Proton Pencil Beam Scanning GRID for Treatment of Bulky Tumors (ProGRID)
-
CLINICAL_TRIALS study record update · 2026-01-29Phase II Study of Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma
-
CLINICAL_TRIALS study record update · 2026-01-28A Phase I Study of a p53MVA Vaccine in Combination With Pembrolizumab
-
CLINICAL_TRIALS study record update · 2026-01-28HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2026-01-28Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
-
CLINICAL_TRIALS study record update · 2026-01-28Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma
-
CLINICAL_TRIALS study record update · 2026-01-26A Study of the Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Features of Atypical/Dysplastic Nevi in Patients With Stage IIB-IIIC Melanoma
-
CLINICAL_TRIALS study record update · 2026-01-22Integrated Cancer Repository for Cancer Research
-
CLINICAL_TRIALS study record update · 2026-01-21A Phase I/Ib, Open-label, Multi-center, Study of DKY709 as a Single Agent and in Combination With PDR001 in Patients With Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2026-01-21Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization
-
CLINICAL_TRIALS study record update · 2026-01-20Correlation Between Early Interval 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (PET/CT) and Circulating Tumor DNA (ctDNA) in Advanced Melanoma Patients Treated With Immune Checkpoint Inhibitors
-
CLINICAL_TRIALS study record update · 2026-01-15Collection of Tissue, Blood and Other Specimens From Patients With Benign and Malignant Tumors of the Soft Tissue, Gastrointestinal Tract, and Other Intra-abdominal Sites.
-
CLINICAL_TRIALS study record update · 2026-01-15Sample Collection for Ongoing Research and Product Evaluation (SCORE) Study
-
CLINICAL_TRIALS study record update · 2026-01-14A Phase 1/2 Open-Label, Dose Finding and Expansion Study to Investigate the Safety and Effectiveness and Determination of the Optimal Dose of N17350 Administered Intratumorally in Participants With Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2026-01-14QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
-
CLINICAL_TRIALS study record update · 2026-01-12Long-term Safety Outcomes in Patients Treated With Replimune Oncolytic Immunotherapy Products
-
CLINICAL_TRIALS study record update · 2026-01-12Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613
-
CLINICAL_TRIALS study record update · 2026-01-12A Phase I/II, Open-label, Dose-escalation and Expansion Study to Assess the Safety, Pharmacokinetics and Clinical Activity of NUC-7738, a Nucleotide Analogue, in Patients With Advanced Solid Tumours and Lymphoma
-
CLINICAL_TRIALS study record update · 2026-01-12A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Treatment-Naïve Unresectable or Metastatic Melanoma
-
CLINICAL_TRIALS study record update · 2026-01-08Phase I Randomized Open Label Trial Investigating Adoptive Transfer of CD39+CD103+CD8+ Tumor-isolated T Cells (AGX148) Alone or Combined With siRNA Modulation of PD-1 (AGX148/PH-762) in Patients With Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2026-01-08A Randomized Study of Urolithin A vs. Placebo in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors
-
CLINICAL_TRIALS study record update · 2026-01-08Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic Therapies
-
CLINICAL_TRIALS study record update · 2026-01-08A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab + Relatlimab Fixed-dose Combination Versus Nivolumab Monotherapy After Complete Resection of Stage III-IV Melanoma
-
CLINICAL_TRIALS study record update · 2026-01-07Measuring Real Time Decision-Making About UVR Protection